Sarepta has become a company that other biopharma companies love to hate, thanks to it having received US Food and Drug Administration approval for three Duchenne muscular dystrophy (DMD) drugs, despite not having (yet) generated Phase III efficacy data for them. (Also see "Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval" - Scrip, 26 February, 2021.)
The firm could earn respect, however, if it can bring to market its DMD gene therapy delandistrogene moxeparvovec (SRP-9001) and...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
